WMHAT IS BVDV?
(see box below). In the same genus are classical swine fever virus and border disease virus. Recently, the
CLASSIFICATION
International Committee on Taxonomy of Viruses has Bovine virus diarrhoea virus (BVDV) is a member proposed that a fourth distinct species containing the of the Pestivirus genus within the family Flaviviridae BVDV group 2 isolates (BVDV-2) be recognised. There -ww f are differences in the geographical distribution of the different BVDV species. BVDV-1 viruses, of which there are at least five serologically distinct subspecies (la to le), have a worldwide distribution; the majority of BVDV isolates found in the UK belong to the la subgroup. BVDV-2 viruses are, as yet, largely restricted to the USA and Canada. Striking differences exist between the disease syndromes following infection with BVDV. Severe outbreaks have been associated with the BVDV-2 species but, more recently, the importance of BVDV-1 isolates in severe outbreaks has also been recognised.
GENOMIC ORGANISATION
BVDV is a small enveloped virus with a genome consisting of a single positive RNA strand of around 12-5 kb. The genome encodes a variety of structural and non-structural proteins (see box, right).
Structural proteins
The structural proteins ultimately assemble to form the virion, in which the major envelope glycoprotein (E2) is anchored in a host-derived lipid bilayer surrounding a capsid containing the newly synthesised viral RNA. E2 is the major target for neutralising antibodies, which confer protection following infection or vaccination. The highly variable nature of epitope-rich regions within the E2 sequence dictate that the E2 protein is the most important source of antigenic variability between different BVDV strains. A second glycoprotein, EO, differs from E2 in that it has no membrane anchor and is most likely to form a non-covalent association with E2 at the virion surface. EQ can be found free in the serum of persistently infected (PI) animals, giving this protein potential as a diagnostic antigen. Antibodies to EQ may also be neutralising.
Non-structural proteins Of the non-structural proteins, the most studied is the NS3 protein, associated with the lytic activity of cytopathic viruses. This protein is both highly conserved and immunogenic, and forms the basis of several commercially available antibody and virus detection assays. Antibodies against NS3/NS2-3 are non-neutralising, but may play an important role in cell-mediated immunity. Non-structural proteins may also be important for major histocompatibility complex restricted cytotoxic T cell killing.
THE BIOTYPES
BVDV may exist as two distinct biotypes: non-cytopathogenic (BVDV nc) and cytopathogenic (BVDV c). The 'nc' biotype causes no cytopathology in cell culture, whereas the 'c' biotype does. It is the non-cytopathogenic biotype that persists in the cattle population (mainly within PI calves) and thereafter gives rise to the cytopathogenic biotype. This occurs through a variety of mutation events, the inevitable consequence of which is the cleavage of the NS2-3 protein and the subsequent separate expression of NS3. These mutations may occur spontaneously through insertion of host protein sequences, duplication of viral genes, or even as point mutations within key areas of the viral genome. The cytopathogenic biotype can also arise through recombination with other BVDV strains (eg, attenuated live vaccine strains). (Olafson and others 1946) ; episodes of agalactia and diarrhoea are not uncommonly-recorded and, more recently, severe and fatal adult disease has been described in the UK following acute infection (David and others 1993, Hibberd and others 1993) .
The importance of acute infections in the transmission and maintenance of BVDV within a herd or population should not be underestimated (Houe 1995) . They are responsible for 93 per cent of all in utero infections that result in the birth of PI calves (Grotelueschen and others 1998) .
SEVERE HAEMORRHAGIC DISEASE
In the late 1980s, an acute and fatal syndrome of veal calves was reported in New York State. It was characterised by a profound thrombocytopenia and haemorrhagic disease. The cause was shown to be a new variant of BVDV and, on the basis of genomic sequence, it was possible to distinguish these isolates; they were subsequently classified as BVDV group 2 (see box, page 176). BVDV-2 viruses have spread across the USA and into Mucosal disease was first reported in 1953 and described as a fatal condition of cattle, characterised by severe erosive lesions in the oral and intestinal mucosa (Ramsey and Chivers 1953) . Over the next 30 years, a series of observations was made about the association between BVDV and mucosal disease. These observations were finally refined into a hypothesis (see box, below right) and proven experimentally. The hypothesis states that an initial transplacental infection of the early fetus with the non-cytopathogenic virus results in the birth of a calf which has a lifelong persistent viraemia. These calves (and only these calves) may later develop mucosal disease as a result of superinfection with a 'homologous' cytopathogenic BVDV. In the field, mucosal disease usually affects animals of six to 18 months of age, although it has been reported in calves of only a few weeks old and in adult cattle aged five to 10 years.
As there are a number of bovine vesicular-like diseases, the following definition of mucosal disease is suggested:
HOW IS BVDV INFECTION DIAGNOSED?
BVDV and BVDV antibodies can readily be detected in both blood and milk samples. These tests are reliable and can be carried out on individual animals or groups of animals (see box on page 185).
WHAT TESTS CAN BE DONE AND WHEN?
The diagnosis of BVDV infection hinges on the identification of virus (using virus isolation, antigen ELISA, polymerase chain reaction [PCR] or immunoperoxidase staining techniques) or evidence of exposure to virus (by antibody ELISA).
Antibody tests, in providing an indication of exposure, are useful in assessing the status of a group of animals or a whole herd prior to, or as a part of, a disease control programme. Tests for BVDV identify those animals that are persistently infected. It is these tests that should be used on a whole herd basis for virus eradication programmes.
Virus detection
The critical reservoir of BVDV is the PI animal. The only certain way of identifying a PI animal is by the demonstration of persisting virus. As the viraemia following acute infection usually lasts no longer than 10 to 14 days, any animal that has a positive viraemia on first sampling and also at a second sampling performed a minimum of three weeks later, can be considered persistently viraemic. These animals usually have a low level or total absence of specific BVDV In addition to submitting a sample of milk from the bulk tank for antibody analysis, milk samples from freshly calved heifers can be taken to obtain further information on disease dynamics. A full explanation of this cohort milk testing is available elsewhere (Pritchard 1998) . Testing of blood samples from a group of six homebred heifers, aged between eight and 18 months, provides further information about the spread of the virus and the likely presence of a PI animal (Houe 1995) .
What are the exceptions for diagnosis? There are a number of clinical situations that provide a challenge for the process of diagnosis. These, together with some suggested courses of action, are highlighted in a box overleaf.
Legal considerations of diagnosis BVDV is a significant pathogen that can affect both male and female cattle. Screening for BVDV should, therefore, be a part of all veterinary 'examinations for fitness' in both male and female animals. Failure to carry this out may have legal implications (Brownlie and others 1984b) .
The situation regarding the sale of PI animals is less clear. To knowingly sell, or advise the sale of, PI animals, in the full knowledge that they are the major reservoir of BVDV, is professionally unsound. Interestingly, in Denmark, bovine virus diarrhoea (BVD) is a notifiable disease and it is illegal to allow, knowingly, a PI animal onto open pastures. However, in the UK it remains that any purchaser who buys an animal in good faith must accept that caveat emptor ('let the buyer beware'). The control programme should be clearly defined and realistic. A well designed programme will increase both the health and profitability of the herd by controlling the effects of BVDV. In certain herds, the objective will be to minimise the economic losses associated with exposure to the virus; in other situations, the objective may be to eliminate the virus from the herd.
The decision about which route to take must take account of farm biosecurity (could it be maintained as a closed unit?) and the management (are replacement cattle bought in and are shared/hired bulls used? The 'do nothing' policy The 'do nothing' option should not be considered a control policy. Where exposure to BVDV is left to chance, the likelihood of acquiring good protective immunity is random, whereas the losses that can occur as a result of infection can be significant. Furthermore, natural immunity will wane and lack of subsequent virus challenge could compromise immune protection. For example, virus has been shown to have re-entered a herd that, three years previously, had undergone a testing and eradication programme. Animals that had tested antibody positive three years earlier were subsequently found to be antibody negative. Seroconversion, associated with ill health, was recorded in a number of these animals (D. Leonard, 1998, personal communication).
Antibody positive (BVDV)
Persistent infection (BVDV)
Use of a Pi animal as a 'vaccinator' In the past, PI animals have been maintained as natural 'vaccinators' within herds as a means of increasing levels of natural immunity in the absence of an effective BVDV vaccine. There have been a number of problems associated with this method of control; not least, naive animals must sustain a period of acute infection before any protective immunity can develop. Acute BVDV infection can compromise cattle health, particularly when the virus gains access to breeding cattle. In some cases, complete seroconversion within the group has not been achieved following PI 'vaccination'. Furthermore, the PI animal can, at any time, develop mucosal disease with fatal consequences. With the availability of efficacious vaccines, this option should not be used.
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No exposure Eradication The routine availability of laboratory tests to determine BVDV status allows the identification and elimination of PI animals. However, as there are exceptions to the definitive determination of PI status (see box on page 184), care must be taken before declaring a herd virus-free. It is vital to remember that all young stock subsequently born onto the farm must be sampled. It is prudent to continue this sampling process in order to monitor the ongoing status of the herd.
The removal of PI animals may not remove all the virus from the farm. The available tests will determine animals with persistent infections but will not reliably detect acute infections. The problem of slow spread of virus by acute infection within the herd, in the absence of a PI animal, has been identified. This would explain those cases where seroconversion to virus has been demonstrated but subsequent whole herd bleeds have failed to identify a PI animal. It is probable that larger herds will be more capable of sustaining an acute infection than smaller herds. For this reason, eradication strategies may achieve more rapid success in smaller herds.
The eradication of PI animals will, in time, lead to the presence of seronegative cattle in the herd that are naive to disease and to a herd that is vulnerable to severe losses should BVDV re-enter the herd. This means that eradication schemes (in the absence of follow-up vaccination) will tend to suit either biosecure herds that have no contact with neighbouring cattle, or closed herds; 
Vaccination
Vaccination to control and prevent BVDV is now both possible and cost effective. BVDV can be vertically transmitted to the next generation via the creation of a PI animal. This means that long-term control hinges on the protection of the breeding herd and the prevention of the birth of new PI animals. The availability of vaccines, which have proven protection against transplacental BVDV infection, represents a major development in the control of this pathogen in cattle.
In the UK, only killed BVDV vaccines (which require a primary course of two injections) have been licensed. It is vital that breeding cattle receive their primary course well before first service. Heifers can be batched as yearlings and receive the primary course in good time before the commencement of service. Thereafter, single booster doses are recommended before subsequent service periods to ensure maximum immunity is present at times of greatest potential risk (ie, the service period and early to mid-pregnancy). However, where losses are ongoing or where known naive animals are at risk of infection, there may be a requirement to vaccinate animals at other stages of the reproductive cycle. Similarly, in herds that are calving all year round it may be more straightforward to block vaccinate the herd.
Thus, for long term control, the breeding herd should be immunised and boosted on a regular basis. In herds where infection is active, there may be a role for vaccinating calves to reduce acute infection. As colostral antibodies can protect against the viraemia of acute infections, an alternative approach to protecting young calves is to booster colostral antibodies by vaccinating the dam.
Live BVDV vaccines are commercially available in some countries. The recommendations attached to some of these vaccines stipulate that they should only be used in animals that have initially been vaccinated with a killed BVDV vaccine. Their use in pregnant animals may be contraindicated.
Eradication and vaccination
Vaccination and eradication are both routes to controlling the losses associated with BVDV. However, they should not be considered to be opposing strategies. Eradication alone leads to a herd which, while free from BVDV, is vulnerable to the reintroduction of virus. Vaccination programmes provide protection to the herd, but vaccination will not alter the status of PI animals that are already in the herd prior to the start of the vaccination programme, nor any PI animals bought into the herd. These PI animals will die in time and their cohorts will be immunised. However, if these PI animals are female and reach breeding age, their progeny will be persistently infected.
The eradication of PI animals, following confirmatory blood testing, can be carried out in combination with vaccination of the breeding herd. This is the 'Rolls Royce' method of BVDV control that will lead to the most rapid and complete resolution of all BVDV-related problems within the herd.
In Practice * APRIL 2000 FUTURE CONSIDERATIONS HEALTH SCHEMES AND NATIONAL ERADICATION Over the past 20 years the whole farming industry has undergone considerable change. It is already clear that there will be significant commercial advantages for the stockowner from membership of farm assurance and health schemes. BVDV is a cause of appreciable economic loss and it is through health schemes and control programmes that knowledge regarding the disease can be translated into improved herd health and profitability. Several European countries have embarked upon BVDV eradication campaigns and the prospect exists that lack of disease control could be used as a barrier to trade. The veterinary profession should be actively involved in herd health schemes, as it is the veterinary surgeon who will be able to provide the expert help and advice that the stockowner requires to implement the most appropriate control policy. It is entirely possible that, in the future, eradication of BVDV in selected areas (presently restricted to the Shetland Islands) or on a national scale will make great demands on cattle healthcare programmes and resources.
BVDV 'MARKER' VACCINES
The monitoring of future eradication schemes will have to utilise assays for BVDV antibody -most likely, the antibody status in bulk milk samples. The concurrent use of vaccines could compromise this monitoring and so, to maintain the protection offered by vaccines during this period, it will be necessary to develop vaccines of 'marker' status. 'Marker' vaccines permit distinction between vaccinal and natural immunity; their construction demands a degree of molecular wizardry and immunological insight! NEW VIRAL VARIANTS AND CONTROL
The emergence of BVDV strains of greater virulence (eg, those isolates causing severe haemorrhagic disease) underlines the need to maintain surveillance, both within the national herd and on the importation of animals and biological materials. At present, isolates in the UK,'and possibly elsewhere, apart from North America, appear to be group 1 viruses. While virulence and antigenicity may not necessarily correlate, the emergence of new antigenic variants may have implications for the design and validation of future vaccines. It is important that veterinary practitioners are provided with full documentation of vaccine usage and vaccine efficacy. Fortunately, there appears, at present, to be considerable cross-protection between BVDV isolates, particularly against isolates in the same viral group (eg, group 1). Present evidence shows that, with the correct selection and use of existing vaccines and eradication programmes, there are excellent prospects for the control of BVDV. SUMMARY BVD is, undeniably, one of the most important viral diseases of cattle. The paradox for diagnosis is that clinical signs range from the inapparent to either severe haemorrhagic disease or fatal mucosal disease, while the immunosuppressive effect of acute BVDV infections can enhance clinical disease from other pathogens. In recent years, there has been a growing awareness of the major role of BVDV in reproductive loss, causing early embryonic loss, abortions and the birth of persistently viraemic calves.
In the pathogenesis of mucosal disease, the two biotypes of the virus, non-cytopathogenic and cytopathogenic, act sequentially. The initial transplacental infection of the early fetus with the non-cytopathogenic virus can result in the subsequent birth of calves persistently viraemic for life with this biotype. These calves may later develop mucosal disease as a result of superinfection with the cytopathogenic virus. For a number of years, the origin of this cytopathogenic virus was suggested to be by mutation from the persisting noncytopathogenic virus. Now that the genomic organisation of several pairs of viral biotypes is known, the mutational origin has been confirmed. The published data on a variety of these mutational rearrangements in different isolates has highlighted the importance of two viral proteins, E2 and NS2-3.
The laboratory tests for both BVDV and viral antibody are excellent. Detection of the PI animal is a central part of all eradication strategies; however, many herds may benefit from an eradication and vaccination programme. The interpretation of antibody titres, as a basis for vaccination in these programmes, may be more complex. This article has described how strategic decisions for BVDV control can be made.
